Company news
Kexing Biopharm Co., Ltd. news in 2026
Kexing Biopharm Co., Ltd.'s news releases, calls and decks from 2026, newest first.
New Opportunities for Global Cooperation: Kexing Biopharm Shines at CPHI Milan 2026
October 10, 2026
(688136)"SHAN DONG KEXING BIOPRODUCTS CO., LTD."Announcement on Voluntary Disclosure of Acceptance of Marketing Authorization Application for Pegylated Human Granulocyte Colony-Stimulating Factor Injection
October 9, 2026
Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China
October 4, 2026
SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for GB20 Injection
September 21, 2026
SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
September 7, 2026
SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
August 21, 2026
SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Announcement on Change of Sponsor Representative for Continuous Supervision
August 7, 2026
SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Announcement on Vesting Results for the 2nd Vesting Period under the 2024 Restricted Stock Incentive Plan and the Listing of Shares
July 7, 2026
SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Announcement on Granting of Restricted Stocks to Incentive Objects
July 2, 2026
Announcement on the Resignation of Core Technical Personnel
June 26, 2026
Beyond Horizons, Forward Together | Kexing Biopharm Concludes Participation in CPHI & PMEC China 2026
June 23, 2026
Announcement on the Achievements of Vesting Conditions in the 2nd Vesting Period of the 2024 Restricted Stock Incentive Plan
June 15, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 7, 2026
Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of GB10 for Injection
May 13, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 12, 2026
Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference
April 28, 2026
2025 Annual Report
April 21, 2026
Announcement on Voluntary Disclosure of GB19 Injection Obtaining FDA Clinical Trial Approval for New Drugs
March 30, 2026
Announcement on Opening a Special Account for Raised Funds and Signing a Tripartite Supervision Agreement on Special Account Deposit of Raised Funds
March 20, 2026
Announcement on Progress and Implementation Result of Shares Repurchase and Share Changes
March 3, 2026
Announcement on Signing Daily Related Party Transaction Agreements
March 2, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GB19 Injection
February 25, 2026
Announcement on Progress in Repurchasing Shares through Call Auction
February 3, 2026
Earnings Preannouncement for 2025
January 30, 2026
Announcement on Estimated Amount of Daily Related Transactions in 2026
December 31, 2025